Microscopic Polyangiitis (MPA) Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Microscopic Polyangiitis (MPA) Treatment Market is segmented By Drug (Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail pharmacies, Online pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Microscopic Polyangiitis (MPA) Treatment Market Growth Demand Outlook
Microscopic Polyangiitis (MPA) Treatment Market size was valued at USD billion in 2021 and is estimated to reach USD billion by 2029, growing at a CAGR of 5.5% during the forecast period (2022-2029). Microscopic polyangiitis (MPA), known as ANCA-associated vasculitis, is a rare disorder characterized by inflammation of the blood vessels that restricts the blood flow and damage vital organs and tissues. Some other forms of ANCA-associated vasculitis include eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA). MPA mostly affects the small to medium-sized blood vessels, particularly involving the kidneys, lungs, nerves, skin, and joints. It can worsen rapidly, so early diagnosis and treatment are essential to prevent kidney or respiratory damage or organ failure. Microscopic polyangiitis can affect both men and women of all ages, but the average age is around 50, and men may get MPA more often. MPA is rare, with prevalence at 1 to 3 cases per 100,000 people in the United States. The incidence is around 2 cases per 100,000 people in the United Kingdom and an estimated 1 case per 100,000 people in Sweden.
MPA is diagnosed by several tests including, the blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for diagnosis of red blood cells (RBCs), and imaging procedures such as computed tomography (CT), magnetic resonance (MR) scan, and X-rays. If these tests are positive for the presence of MPA, biopsy (tissue sample testing) is performed to confirm the presence of MPA.
As per DataM Intelligence, Microscopic Polyangiitis (MPA) Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Microscopic Polyangiitis (MPA) Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Microscopic Polyangiitis (MPA) Treatment Market in the United States and Canada produces the utmost share. Whereas the European Microscopic Polyangiitis (MPA) Treatment Market is projected to continue its presence globally during the period of 2022- 2029.
Microscopic Polyangiitis (MPA) Treatment Market - Strategic Insights
|
Metrics |
Details |
|
Market CAGR |
5.5% |
|
Segments Covered |
By Drug, By Route of Administration, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To know more insights into Market, Get Our Sample Brochure
Market Dynamics
The global microscopic polyangiitis (MPA) treatment market growth driven by certain factors such as rising prevalence of chronic diseases with growing geriatric population, technological advancement in cell isolation, increasing demand for biopharmaceuticals, and increasing stem cell research. are among the key factors driving the market growth.
Rising development of new treatments for MPA and robust pipeline drugs, is expected to drive the global microscopic polyangiitis (MPA) treatment market during the forecast period
Some of the pipeline drugs for treating microscopic polyangiitis are Abatacept, IFX 1, among others. In July 2018, InflaRx N.V., a German clinical-stage bio-pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for conducting phase II clinical trials of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of ANCA indicates that the patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes the C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatments for MPA is expected to boost the microscopic polyangiitis market's growth over the forecast period.
The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), among others for several drugs for the treatment of MPA, is further driving the growth of the market. For instance, in October 2018, Genentech received the U.S. Food and Drug Administration (FDA) approval to update the Rituxan label to include the follow-up treatment information of adult patients suffering from granulomatosis with polyangiitis and microscopic polyangiitis (MPA), who had shown improvement in medical condition with the glucocorticoid and cyclophosphamide induction treatment.
Side-effects associated with the drugs hampering the growth of the microscopic polyangiitis (MPA) treatment market
However, the global microscopic polyangiitis market growth is hindered by some factors, including side-effects caused by the drugs. Some of the side-effects caused by corticosteroids include skin thinning and intense pain. Monoclonal antibody production involves costly and time-consuming research. Azathioprine involves side effects such as diarrhea, joint pain, loss of coordination, seizure, and vision changes.
Industry Analysis
The global microscopic polyangiitis (MPA) treatment market provides in-depth analysis of the market based on various industry factors such as porter’s five force analysis, supply chain analysis, regulatory analysis, pricing analysis, patent analysis, epidemiology, unmet needs.
Segment Analysis
The drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The treatment of microscopic polyangiitis is based on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids such as prednisone combined with other medications that suppress the immune system and reduce inflammation. However, even with treatment, MPA is a chronic condition with periods of relapse and remission, so ongoing medical care and monitoring are necessary. Some of the drugs available for MPA treatment are Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, and others. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab to treat MPA and GPA. (Biologic medications are complex proteins derived from living organisms. They target certain parts of the immune system to control inflammation.). Rituximab is expected to gain maximum share over the forecast period (2020-2027).
On the other hand, cyclophosphamide is growing at a significant growth rate over the forecast period. It is a chemotherapy-type drug that blocks the abnormal growth of certain cells in the body in combination with prednisone. Prednisone is typically started at a high dose and then tapered off slowly. Cyclophosphamide lowers the body’s ability to fight infection, hence usually limited to a three- to six-month period and replaced by less toxic medications such as mycophenolate mofetil azathioprine, or methotrexate, a drug commonly used to treat rheumatoid arthritis. Some milder forms of MPA are typically treated with a combination of prednisone and methotrexate.
Geographical Analysis
North America region holds the largest market share of the global microscopic polyangiitis (MPA) treatment market
North American region is dominating the global microscopic polyangiitis (MPA) treatment market accounting for the maximum market share in 2022 due to the increasing development of drugs to treat MPA. In the United States, the annual incidence of microscopic polyangiitis is 3.6 cases per million persons, and the prevalence is one to three cases per 100,000 population. In September 2022, Roche received the U.S. Food and Drug Administration (FDA) approval for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age and older.
Competitive Landscape
The microscopic polyangiitis (MPA) treatment market is highly competitive and consists of several major players and new players in the market. Some of the key players which are contributing to the growth of the market are ChemoCentryx Inc., Celltrion, Inc., Teijin Pharma Ltd, Sandoz International GmbH (Novartis Division), TTY Biopharm Company Ltd, Genentech, Inc., InflaRx N.V., Bristol-Myers Squibb Company, Amerigen Pharmaceuticals Limited, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, contributing to the growth of the microscopic polyangiitis (MPA) treatment market globally. For instance,
On 4th May 2020, Israeli generics giant Teva Pharmaceutical Industries and partner, South Korean biotechnology company Celltrion, launched their rituximab biosimilar Truxima (TL011) in the US. Truxima (rituximab-abbs) is now available in the US for the treatment of patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (Wegener’s granulomatosis), and microscopic polyangiitis.
In January 2020, Pfizer announced to introduce three new biosimilars this year. The company plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr), Rituxan biosimilar Ruxience (rituximab-pvvr), and Herceptin biosimilar Trazimera (trastuzumab-qyyp). The audience is available to treat adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.
Global Microscopic Polyangiitis (MPA) Treatment Market – Key Companies to Watch
Celltrion Inc
Overview: Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Jung Jin Seo, is the richest person in South Korea.
Product Portfolio: Truxima (rituximab)- Targets a specific protein in the immune system that may trigger inflammation of the blood vessels.
The global microscopic polyangiitis (MPA) treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages
Frequently Asked Questions
What is the Microscopic Polyangiitis (MPA) Treatment Market growth?
The market is growing at a CAGR of 5.5%.
Who are the key players in Microscopic Polyangiitis (MPA) Treatment Market?
ChemoCentryx Inc., Celltrion, Inc., Teijin Pharma Ltd, Sandoz International GmbH (Novartis Division), TTY Biopharm Company Ltd.